Role of Exenatide in Type 1 Diabetes

NCT00456300 · Completed

Last updated 2026-05-28

This clinical trial tested whether adding exenatide (a medication) to insulin therapy helps manage blood sugar levels in adults with type 1 diabetes.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 11 people

Who can join Ages 12–21 · all sexes

Timeline Started 2007-03 · est. completion 2009-03

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT00456300 ↗

Description as written by the study sponsor.

The purpose of this study is to see if giving exenatide and insulin before a meal would lower blood sugars after the meal. This study may help in developing new treatments to help control high blood sugars after meals. This may help improve overall blood sugar control and prevent the long-term effects of diabetes.

Treatments tested

Exenatide also known as Byetta Drug

In each intervention arm the participant receives a different dose (1.25 or 2.5 mcg) of exenatide.
Insulin Drug

Each subject received a baseline study with insulin alone

Main thing measured	Mean Plasma Glucose Area Under the Curve (AUC) for Blood Glucose Concentration in the Exenatide 1.25 mcg or Exenatide 2.5 mcg Treated Groups Along With Insulin, Compared to Insulin Alone
Sponsor	Montefiore Medical Center
Conditions studied	Type 1 Diabetes
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00456300 ↗